Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.65 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 8/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.43 |
| ▸ | PNMT | P11086 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2993408 | 0.89 | ESR1 (0.68) | ESR1ESR2PKMCA12CA1 | |
| SCHEMBL11477876 | 0.88 | ESR1 (0.67) | ESR1ESR2PKMCA12CA1 | |
| Dimethylamine SCHEMBL6529354 | 0.87 | ESR1 (0.62) | ESR1ESR2PKMCA12CA1 | |
| SCHEMBL490066 | 0.87 | ESR1 (0.65) | ESR1ESR2PKMCA12CA1 | |
| SCHEMBL20681402 | 0.87 | ESR1 (0.65) | ESR1ESR2PKMCA12CA1 | |
| SCHEMBL30770403 | 0.87 | ESR1 (0.65) | ESR1ESR2PKMCA12CA1 | |
| SCHEMBL30408119 | 0.87 | ESR1 (0.65) | ESR1ESR2PKMCA12CA1 | |
| SCHEMBL6297841 | 0.86 | ESR1 (0.61) | ESR1ESR2PKMCA12CA1 | |
| SCHEMBL10154278 | 0.86 | ESR1 (0.61) | ESR1ESR2PKMCA12CA1 | |
| SCHEMBL1487369 | 0.84 | ESR1 (0.58) | ESR1ESR2PKMCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325962-A1 | TYROSINE DERIVATIVE | GENENTECH, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090325962-A1 | TYROSINE DERIVATIVE | GENENTECH, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-7595399-B2 | Tyrosine derivatives | GENENTECH, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595399-B2 | Tyrosine derivatives | GENENTECH, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-7524839-B2 | Compounds, their use and preparation | BIOVITRUM AM (PUBL.) | 2009-04-28 | — | — | US | disclosed |
| US-7524839-B2 | Compounds, their use and preparation | BIOVITRUM AM (PUBL.) | 2009-04-28 | — | — | US | disclosed |
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | GENENTECH, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | GENENTECH, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| EP-1214292-B1 | TYROSINE DERIVATIVES | GENENTECH INC (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2005113003-A2 | METHOD FOR AUGMENTING B CELL DEPLETION | GENENTECH, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325962-A1 | TYROSINE DERIVATIVE | VCAM1, ICAM1, ITGB4 | ESR1 2963/4885ESR2 2413/4885PKM 2911/4885 |
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | CD22, ITGAM, FCGR3B | ESR1 3392/4885ESR2 1740/4885PKM 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.